Rialto Wealth Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Rialto Wealth Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38	Buy	+1	New	+$37	﹤0.01%	1925

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rialto Wealth Management's CRNX Position: Q2 2026 in Review

Rialto Wealth Management opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 1 share worth $38. The stake represents ﹤0.01% of the portfolio and ranks #1925 among its holdings.

266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Rialto Wealth Management held 1 share of Crinetics Pharmaceuticals worth $38 as of Q2 2026.
Crinetics Pharmaceuticals was a new Rialto Wealth Management position in Q2 2026.
Crinetics Pharmaceuticals made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1925 holding.
266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.